|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/19/17 Acer Therapeutics Inc. S-4 91:8M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: S-4 Registration of Securities Issued in a HTML 2.60M
Business-Combination Transaction
2: EX-2.4 Plan of Acquisition, Reorganization, Arrangement, HTML 150K
Liquidation or Succession
3: EX-5.1 Opinion of Counsel re: Legality HTML 25K
4: EX-8.1 Opinion of Counsel re: Tax Matters HTML 27K
5: EX-8.2 Opinion of Counsel re: Tax Matters HTML 34K
6: EX-10.16 Material Contract HTML 94K
7: EX-10.17 Material Contract HTML 133K
8: EX-10.18 Material Contract HTML 28K
9: EX-10.19 Material Contract HTML 31K
10: EX-10.20 Material Contract HTML 31K
11: EX-10.21 Material Contract HTML 42K
12: EX-10.22 Material Contract HTML 60K
13: EX-10.23 Material Contract HTML 29K
14: EX-10.24 Material Contract HTML 26K
15: EX-10.25 Material Contract HTML 76K
16: EX-10.26 Material Contract HTML 29K
17: EX-10.27 Material Contract HTML 54K
18: EX-10.28 Material Contract HTML 54K
19: EX-10.29 Material Contract HTML 43K
20: EX-10.30 Material Contract HTML 99K
21: EX-10.31 Material Contract HTML 96K
22: EX-10.32 Material Contract HTML 94K
23: EX-10.33 Material Contract HTML 94K
24: EX-10.34 Material Contract HTML 94K
25: EX-10.35 Material Contract HTML 26K
26: EX-23.1 Consent of Experts or Counsel HTML 23K
27: EX-23.2 Consent of Experts or Counsel HTML 22K
28: EX-99.1 Miscellaneous Exhibit HTML 36K
29: EX-99.4 Miscellaneous Exhibit HTML 23K
30: EX-99.5 Miscellaneous Exhibit HTML 23K
31: EX-99.6 Miscellaneous Exhibit HTML 23K
32: EX-99.7 Miscellaneous Exhibit HTML 23K
33: EX-99.8 Miscellaneous Exhibit HTML 23K
34: EX-99.9 Miscellaneous Exhibit HTML 23K
41: R1 Document and Entity Information HTML 36K
42: R2 Consolidated Balance Sheets HTML 78K
43: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
44: R4 Consolidated Statements of Operations HTML 56K
45: R5 Consolidated Statements of Changes in HTML 63K
Stockholders' Equity
46: R6 Consolidated Statements of Cash Flows HTML 104K
47: R7 Business Overview, Going Concern and Summary of HTML 57K
Accounting Policies
48: R8 Cash and Cash Equivalents HTML 28K
49: R9 Other Current Assets HTML 31K
50: R10 Property and Equipment HTML 39K
51: R11 Other Long-Term Assets HTML 26K
52: R12 Notes Payable HTML 29K
53: R13 Income Taxes HTML 36K
54: R14 Commitments and Contingencies HTML 34K
55: R15 Significant Contractual Service and Milestone HTML 30K
Agreements
56: R16 Equity HTML 50K
57: R17 Options and Warrants HTML 86K
58: R18 Licenses HTML 28K
59: R19 Subsequent Events HTML 30K
60: R20 Basis of Presentation and Going Concern HTML 34K
61: R21 Other Current Assets HTML 32K
62: R22 Business Overview, Going Concern and Summary of HTML 105K
Accounting Policies (Policies)
63: R23 Other Current Assets (Tables) HTML 33K
64: R24 Property and Equipment (Tables) HTML 36K
65: R25 Income Taxes (Tables) HTML 32K
66: R26 Commitments and Contingencies (Tables) HTML 29K
67: R27 Options and Warrants (Tables) HTML 72K
68: R28 Business Overview, Going Concern and Summary of HTML 68K
Accounting Policies (Detail)
69: R29 Cash and Cash Equivalents - Additional Information HTML 31K
(Detail)
70: R30 Other Current Assets (Details) (Detail) HTML 32K
71: R31 Other Current Assets- Additional Information HTML 45K
(Detail)
72: R32 Property and Equipment (Detail) HTML 57K
73: R33 Property and Equipment - Additional Information HTML 41K
(Detail)
74: R34 Other Long Term Assets (Detail) HTML 26K
75: R35 Notes Payable - Additional Information (Detail) HTML 33K
76: R36 Income Taxes - Additional Information (Detail) HTML 28K
77: R37 Income Taxes (Detail) HTML 39K
78: R38 Commitments and Contingencies - Additional HTML 37K
Information (Detail)
79: R39 Commitments and Contingencies (Detail) HTML 37K
80: R40 Significant Contractual Service and Milestone HTML 32K
Agreements - Additional Information (Detail)
81: R41 Equity - Additional Information (Detail) HTML 104K
82: R42 Stock-Based Compensation - Additional Information HTML 207K
(Detail)
83: R43 Options and Warrants - Stock Option Activity HTML 73K
(Detail)
84: R44 Options and Warrants - Warrant Activity (Detail) HTML 62K
85: R45 Licenses - Additional Information (Detail) HTML 36K
86: R46 Subsequent Events - Additional Information HTML 53K
(Detail)
87: R47 Basis of Presentation and Going Concern - HTML 39K
Additional Information (Detail)
88: R48 Significant Accounting Polices - Additional HTML 30K
Information (Detail)
90: XML IDEA XML File -- Filing Summary XML 113K
89: EXCEL IDEA Workbook of Financial Reports XLSX 58K
35: EX-101.INS XBRL Instance -- opxa-20170331 XML 896K
37: EX-101.CAL XBRL Calculations -- opxa-20170331_cal XML 134K
38: EX-101.DEF XBRL Definitions -- opxa-20170331_def XML 365K
39: EX-101.LAB XBRL Labels -- opxa-20170331_lab XML 910K
40: EX-101.PRE XBRL Presentations -- opxa-20170331_pre XML 646K
36: EX-101.SCH XBRL Schema -- opxa-20170331 XSD 144K
91: ZIP XBRL Zipped Folder -- 0001193125-17-231365-xbrl Zip 116K
| EX-10.18 |
Exhibit 10.18
FIRST AMENDMENT TO LICENSE AGREEMENT
This First Amendment (hereinafter called “the First Amendment”) to the License Agreement, as defined below, to be effective as of the 28 day of April, 2014 (hereinafter called “Agreement Date”), is by and between Baylor College of Medicine (hereinafter called “ BCM”), a Texas nonprofit corporation having its principal place of bus iness at One Baylor Plaza , Houston, Texas 77030, and Acer Therapeutics Inc., a corporation organized und er the laws of Delaware and having a principal place of business at 222 Third St., Suite 2240, Cambridge, MA 02142, and its Affiliates (hereinafter, collectively referred to as “LICENSEE”).
WHEREAS, BCM and LICENSEE have entered into that certain agreement effective April 4, 2014 (“License Agreement”) under which LICENSEE has obtained from BCM and BCM has granted to LICENSEE a certain exclusive lice nse to the Patent Rights and Subject Technology as defined in said License Agreement; and
WHEREAS, BCM and LICENSEE desire to amend said License Agreement as provided herein.
NOW, THEREFORE, in consideration of the mutual provisions and covenants contained herein , BCM and LICENSEE hereby agree as follows:
| 1. | The terms in the License Agreement shall have the same meanings in this First Amendment. |
| 2. | Paragraph 17.6 is hereby incorporated into the License Agreement and shall read as follows: |
17.6 Provision of Clinical Data. Pursuant to Paragraph l.10 herein, Subject Technology and Confidential Information includes data and results with respect to the ongoing study: http://www.cl inicaltrials.gov/ct2/show/NCTOl 529060?term=maple+syrup&rank= l LICENSEE has requested or will request the interim data recorded for this trial (referred to herein as “ Interim Data”). Specifically for the Interim Data, LICENSEE and BCM agree that the Interim Data will be provided to LICENSEE directly by Dr. Vernon Reid Sutton of BCM and LICNESEE will limit disclosing this Interim Data pursuant to this Section 17. LICENSEE also agrees that under no circumstances shall the Interim Data be disclosed to or discussed with the Developers or any other person performing work on the clinical trial, including physicians, nurses, researchers, clinical staff or administrators.
| 3. | Except as amended hereby, the License Agreement shall be and remain in full force and effect. |
| 4. | The first Amendment shall be effective as of the Agreement Date provided above. |
IN WITNESS WHEREOF, the Parties hereto have executed and delivered this First Amendment in multiple originals by their duly authorized officers and representatives on the respective dates shown below, but effective as of the Agreement Date.
| ACER THERAPEUTICS INC. | BAYLOR COLLEGE OF MEDICINE | |||||
| Name: | /s/ Harry S. Palmin |
Name: | /s/ Adam Kuspa | |||
|
|
Adam Kuspa | |||||
| Title: | President & CEO
|
Title: | Senior Vice President, Research | |||
| Date: | 4/30/14 | Date: | 4/28/14 | |||
01.12.2012 ACER THERAPEUTICS INC BLG 05-078
| This ‘S-4’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/19/17 | 8-K | ||
| 4/4/14 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/27/23 Acer Therapeutics Inc. 10-K 12/31/22 68:13M Donnelley … Solutions/FA 3/02/22 Acer Therapeutics Inc. 10-K 12/31/21 61:12M ActiveDisclosure/FA 3/03/21 Acer Therapeutics Inc. S-1 3:645K Donnelley … Solutions/FA 3/01/21 Acer Therapeutics Inc. 10-K 12/31/20 60:8.9M ActiveDisclosure/FA |